Skip to content Skip to footer
Subscribe Now
Exclusive Interview_Shmulik Shapiro
EXCLUSIVE

Shmulik Shapiro, EVP of Business Development & Strategy at RSIP Vision Shares Insight on New AI Tool for Prostate MRI Analysis that Supports PI-RADS Scoring

Shots: Shmulik spoke about the key features and development of the new AI tool for Prostate MRI Analysis Shmulik emphasized the significance of this new tool in PI-RADS score and how this can be helpful in diagnosing prostate lesions in MRI The interview provides a deeper understanding of medical imaging technologies that are emerging through…
July 25, 2022

Read more

PharmaShots Interview Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate Cancer Shots: The company reported the importance of precision medicine and prognostic tests that can help to determine cancer & enables personalized treatment paths. The company highlights the ability of genetic…
February 9, 2022

Read more

Viewpoints_Denis Corin
VIEWPOINTS

PharmaShots Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement for Strontium89 with the US Department of Defense and Veterans Affairs. Shots: BioMed has signed a 5-year agreement to commercially serve the US Department of Veterans Affairs (VA) and Department of Defense…
July 13, 2021

Read more

Viewpoints_Dr. Todd D. Cohen
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Dr. Todd D. Cohen Shares Insight on Prolaris Test’s Ability to Guide Prostate Cancer Treatment

In an interview with PharmaShots, Dr. Todd D. Cohen, M.D., VP Medical Affairs and Medical Director of Urology at Myriad Genetics shared his views on the ability of a biomarker test to predict which men with aggressive prostate cancer will benefit from advanced hormonal therapy and which men with lower-risk prostate cancer can safely avoid such treatments.…
March 25, 2021

Read more